These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33100356)

  • 21. Availability of pediatric-evaluated formulations in Serbia.
    Božić B; Stupar S; Stupar D; Babić U; Bajčetić M
    Indian J Pharmacol; 2017; 49(2):189-193. PubMed ID: 28706333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Systematic Review of the Stability of Extemporaneous Pediatric Oral Formulations.
    Belayneh A; Tessema Z
    ScientificWorldJournal; 2021; 2021():8523091. PubMed ID: 34955693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric Oral Formulations: An Updated Review of Commercially Available Pediatric Oral Formulations Since 2007.
    Strickley RG
    J Pharm Sci; 2019 Apr; 108(4):1335-1365. PubMed ID: 30447227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Formulation and Clinical Evaluation of Sodium Benzoate Oral Solution for the Treatment of Urea Cycle Disorders in Pediatric Patients.
    Maines E; Urru SAM; Burri E; Piccoli G; Pedrolli A; Pasqualini A; Burlina AL; Temporin G
    AAPS PharmSciTech; 2020 Mar; 21(3):100. PubMed ID: 32152836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barriers to administering non-oral formulations in a paediatric population: A semi-structured interview study.
    Venables R; Batchelor H; Stirling H; Marriott J
    Int J Pharm; 2016 Jan; 497(1-2):12-7. PubMed ID: 26611666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Availability of age-appropriate paediatric formulations in the Netherlands: the need in daily clinical practice remains.
    van der Vossen A; Buljaç S; Akçay K; Brugma JD; Vulto A; Hanff L
    Eur J Hosp Pharm; 2021 Nov; 28(6):306-312. PubMed ID: 34697046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Children's medicines in Tanzania: a national survey of administration practices and preferences.
    Adams LV; Craig SR; Mmbaga EJ; Naburi H; Lahey T; Nutt CT; Kisenge R; Noel GJ; Spielberg SP
    PLoS One; 2013; 8(3):e58303. PubMed ID: 23484012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From paediatric formulations development to access: Advances made and remaining challenges.
    Litalien C; Bérubé S; Tuleu C; Gilpin A; Landry ÉK; Valentin M; Strickley R; Turner MA
    Br J Clin Pharmacol; 2022 Oct; 88(10):4349-4383. PubMed ID: 35229891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updating formulations for compounded oral liquid medications in a university health system.
    Stumpf JL; Leja N; Ciarkowski SL; Salah S; Schaeffler KL
    Am J Health Syst Pharm; 2018 Sep; 75(18):1394-1398. PubMed ID: 30006436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current Status of Pediatric Formulations for Chronic and Acute Children' Diseases: Applications and Future Perspectives.
    Siafaka P; Ipekci E; Caglar EŞ; Ustundag Okur N; Buyukkayhan D
    Medeni Med J; 2021; 36(2):152-162. PubMed ID: 34239768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paediatric Medicines - Regulatory Drivers, Restraints, Opportunities and Challenges.
    Vieira I; Sousa JJ; Vitorino C
    J Pharm Sci; 2021 Apr; 110(4):1545-1556. PubMed ID: 33421435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Trends and Emerging Priorities in Compounded Preparations for Children.
    Parrish RH
    Int J Pharm Compd; 2018; 22(5):358-366. PubMed ID: 30384335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Formulation for Pediatric Oral Antimicrobial Agents in Japan: Current Status, Prospects, and Challenges.
    Saito J; Shoji K; Miyairi I; Yamatani A
    Pediatr Infect Dis J; 2023 Aug; 42(8):e298-e303. PubMed ID: 37343212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric drug data in Canadian drug monographs: a descriptive analysis.
    Raja P; Duffett M; Mazer-Amirshahi M; Patel A; Gilpin A; Litalien C; Chan AK; van den Anker J; Lacaze-Masmonteil T; Samiee-Zafarghandy S
    CMAJ Open; 2020; 8(3):E522-E529. PubMed ID: 32873580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Manipulations and age-appropriateness of oral medications in pediatric oncology patients in Sweden: Need for personalized dosage forms.
    Johannesson J; Hansson P; Bergström CAS; Paulsson M
    Biomed Pharmacother; 2022 Feb; 146():112576. PubMed ID: 35062056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.
    Gerrard SE; Walsh J; Bowers N; Salunke S; Hershenson S
    Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31597277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.